Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests that the emulsion extract of brevilin A from Centipeda minima may stimulate hair regrowth in individuals with mild to moderate vertex balding by inhibiting JAK3.

This study found that Centipeda minima and brevilin A significantly reduced oxidative stress and inflammation in human dermal fibroblasts, suggesting their potential to protect against skin aging and inflammation.

This study documented successful use of Brevilin-A, a topical treatment, in pediatric patients with alopecia areata, indicating it as a potentially safe and effective option for managing mild-moderate cases and resistant forms of the disease.

This study found that Centipeda minima extract promotes hair growth by activating Wnt/β-catenin, ERK, and JNK signaling pathways in human hair follicle dermal papilla cells.

This paper reviews current and developing treatments for severe alopecia areata but reports no new clinical findings; the authors highlight the need for standardized treatment protocols.

This narrative review reports that well-selected plant extracts and their active compounds may improve hair health by promoting hair growth and preventing hair loss, potentially aiding in developing targeted therapies for alopecia.

In this study, the alcoholic extract DN106212 from Centipeda minima was shown to be more effective in promoting hair growth in C57BL/6 mice compared to dimethyl sulfoxide and tofacitinib, suggesting its potential as a natural hair growth agent.

This study suggests that phytochemicals from natural sources could be safer alternatives to conventional treatments for hair loss, as they may activate key pathways involved in hair growth.

This review discusses factors affecting hair health, types of alopecia, and the potential of phytochemicals in managing hair loss but reports no new clinical results; it highlights the need for further studies.

This literature review reports that certain herbal remedies, such as rosemary, green tea, and ginseng, have shown promise in promoting hair growth and improving hair density, though variability and study design limitations highlight the need for more rigorous research.

This study found that Kyoh®, a flavonol-rich extract from rocket leaves, may promote hair growth by enhancing the expression of hair growth-related genes in laboratory conditions.

This review highlights the therapeutic potential of hair follicle stem cells in tissue repair and hair regeneration, discussing the molecular mechanisms and the impact of natural compounds on stem cell properties, which may support the development of novel hair loss treatments.

In this study, brepocitinib was found to significantly reduce inflammatory biomarker CCL5 expression and improve clinical severity by week 24, while maintaining a favorable safety profile.

Brepocitinib improves cicatricial alopecia and reduces key immune markers.

In this study, novel mutations in the BTD gene were identified in a patient with profound biotinidase deficiency, highlighting the importance of biotinidase activity measurement and mutation analysis for early diagnosis.

This study suggests that Breezula® and Minoxidil both enhance hair growth in male pattern hair loss by promoting keratinocyte proliferation, with Breezula® potentially more potent in reducing the hair growth inhibitor IL-6.

This study found that treatment with ritlecitinib or brepocitinib was effective in improving scalp hair loss for patients with alopecia areata over 24 weeks compared to placebo.

This study suggests that basonuclin in keratinocytes is likely a regulatory molecule linked to maintaining proliferative capacity and preventing terminal differentiation rather than a cell cycle marker.

This study reports the first successful use of zanubrutinib to treat a 15-year-old Chinese girl with severe refractory Evans' syndrome, resulting in a sustained recovery of platelet counts and haemoglobin levels.

This study found that the oral JAK inhibitors ritlecitinib and brepocitinib were effective in maintaining hair regrowth in alopecia areata with continuous use, though efficacy decreased after withdrawal.

This paper discusses a structure-based analysis to find new BRD4 inhibitors, identifying finasteride and amentoflavone as promising candidates for BET inhibition.

A bull with a gene mutation was asymptomatic, synthetic retinoids cause hair loss, and new therapeutic targets were identified for skin diseases.

TRIV-509 quickly improves skin barrier and cell health in atopic dermatitis.

VYN201 shows promise as a safe and effective treatment for non-segmental vitiligo.

Brepocitinib reduces interferon signaling in hidradenitis suppurativa patients.

This study identified KLHL24 as a new gene linked to a subtype of epidermolysis bullosa simplex, highlighting its role in unresolved cases by involving a degradation-resistant truncated protein impacting keratin turnover.

This study observed that both ritlecitinib and brepocitinib improved scalp biomarkers in patients with alopecia areata, with associations to hair regrowth seen in this phase 2a trial.

This study demonstrated that de novo designed bifunctional proteins can target and degrade BCL-xL, leading to cell apoptosis, suggesting a new approach to targeted protein degradation therapy.

This study compared JAK inhibitors for moderate-to-severe alopecia areata and found brepocitinib 30mg and deuruxolitinib 12mg to be most effective, though deuruxolitinib may cause more adverse events. Further research is needed for long-term efficacy and safety.

This study suggests that biotin therapy may be beneficial for individuals with partial biotinidase deficiency, as some developed symptoms later, which resolved with treatment.